Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-07-08
DOI
10.3389/fimmu.2021.686031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
- (2021) Stephen M Ansell et al. CLINICAL CANCER RESEARCH
- Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
- (2020) Linlin Ma et al. JOURNAL OF NANOBIOTECHNOLOGY
- Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
- (2020) Hyunbo Shim Biomolecules
- Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies
- (2020) Yu-Chin Liu et al. Cells
- Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
- (2020) Yan Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
- (2020) Shuyu Huang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Delivery technologies for cancer immunotherapy
- (2019) Rachel S. Riley et al. NATURE REVIEWS DRUG DISCOVERY
- Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma
- (2019) Suchismita Mohanty et al. Cell Death & Disease
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
- (2019) Branimir I. Sikic et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in immunotherapy delivery from implantable and injectable biomaterials
- (2019) David G. Leach et al. Acta Biomaterialia
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Lack of the hyaluronan receptor CD44 affects the course of bacterial otitis media and reduces leukocyte recruitment to the middle ear
- (2019) Hyun Woo Lim et al. BMC IMMUNOLOGY
- THE NOVEL BISPECIFIC CD47-CD19 ANTIBODY TG-1801 POTENTIATES THE ACTIVITY OF UBLITUXIMAB-UMBRALISIB (U2) DRUG COMBINATION IN PRECLINICAL MODELS OF B-NHL
- (2019) E. Normant et al. HEMATOLOGICAL ONCOLOGY
- First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
- (2019) Vamsidhar Velcheti et al. Immunotherapy
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Matthew Lunning et al. BLOOD
- Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates: A review of recent advances and future perspectives
- (2019) Kenichiro Todoroki et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
- (2019) Suresh de Silva et al. Cancer Immunology Research
- A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index
- (2018) Yun Yang et al. BIOTECHNOLOGY LETTERS
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia
- (2018) Vanessa Buatois et al. MOLECULAR CANCER THERAPEUTICS
- Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
- (2018) Xiaojuan Liu et al. Cell Reports
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
- (2018) Daniel G. Guy et al. Current Hematologic Malignancy Reports
- Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
- (2018) Hanne Locy et al. Frontiers in Immunology
- Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
- (2018) George Fromm et al. Journal for ImmunoTherapy of Cancer
- The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
- (2017) Hanke L. Matlung et al. IMMUNOLOGICAL REVIEWS
- Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses
- (2017) Boning Liu et al. mAbs
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
- (2017) Elie Dheilly et al. MOLECULAR THERAPY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
- (2017) Paola A. Betancur et al. Nature Communications
- “NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results
- (2016) Archana Thakur et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation
- (2016) Jonathan T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
- (2015) Emily C Piccione et al. mAbs
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
- (2014) Christoph Reissfelder et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Monoclonal antibodies in oncology therapeutics: present and future indications
- (2013) Divaya Bhutani et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
- (2013) D. Tseng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
- (2013) K. Weiskopf et al. SCIENCE
- Advances in bispecific biotherapeutics for the treatment of cancer
- (2012) Chad May et al. BIOCHEMICAL PHARMACOLOGY
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
- (2012) B. Edris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
- (2011) M. P. Chao et al. BLOOD
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
- (2010) Mark P. Chao et al. CANCER RESEARCH
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
- (2010) M. P. Chao et al. Science Translational Medicine
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search